Palladia 50 mg - Film-coated tablet

Authorised

- Toceranib phosphate

Product identification

Medicine name:
Palladia 50 mg - Film-coated tablet

Active substance:
Toceranib phosphate

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Toceranib phosphate
62.34 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Film-coated tablet

Withdrawal period by route of administration:

Oral use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QL01EX90

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Available in:
Belgium , Cyprus , Greece , Italy , Luxembourg , Netherlands , Poland , Spain , United Kingdom (Northern Ireland)

Package description:
Packaging:Blister (Alu/PVC), Package_size:20 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
23/09/2009

Manufacturing sites for batch release:
Pfizer Italia S.r.l.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
23/09/2009

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 17/03/2025
Download

ema-puar-palladia-v-150-par-en.pdf